Overview

Efficacy and Safety of DA-2802 in Chronic Hepatitis B Patients

Status:
Completed
Trial end date:
2019-07-15
Target enrollment:
Participant gender:
Summary
A study demonstrates the non-inferiority of DA-2802 when compared with ㅍViread® in chronic hepatitis B patients
Phase:
Phase 3
Details
Lead Sponsor:
Dong-A ST Co., Ltd.
Treatments:
Tenofovir